News from mirati therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 04, 2015, 08:00 ET

Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX),  a targeted oncology company focusing on genetic and epigenetic drivers of cancer,...

May 30, 2015, 09:16 ET

Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data that demonstrated preliminary evidence of clinical activity from its...

May 27, 2015, 08:00 ET

Mirati Therapeutics To Present At The Jefferies 2015 Global Healthcare Conference

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 at...

May 13, 2015, 17:05 ET

Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that the Company will provide an update on its investigational targeted...

May 06, 2015, 16:01 ET

Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2015 and provided...

Mar 11, 2015, 08:00 ET

Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and twelve months ended December 31,...

Feb 03, 2015, 16:01 ET

Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,587,500...

Jan 29, 2015, 16:01 ET

Mirati Therapeutics to Present at the Leerink Global Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the Leerink Global...

Jan 29, 2015, 08:00 ET

Mirati Therapeutics Prices Public Offering of Common Stock

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common...

Jan 28, 2015, 16:01 ET

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its...

Jan 07, 2015, 08:00 ET

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to...

Jan 06, 2015, 08:00 ET

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Memorial Sloan Kettering...

Dec 23, 2014, 08:00 ET

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a...

Nov 19, 2014, 08:00 ET

Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper...

Nov 10, 2014, 08:00 ET

Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and...

Nov 06, 2014, 08:00 ET

Michael Grey Joins Mirati Therapeutics Board of Directors

- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of...

Sep 10, 2014, 08:00 ET

Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st...

Sep 04, 2014, 08:00 ET

Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the...

Aug 11, 2014, 08:00 ET

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum...

Aug 08, 2014, 08:00 ET

Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided...